¶ Proteostasis and ERAD Pathway in Neurodegeneration
Proteostasis And Erad Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Proteostasis (protein homeostasis) refers to the cellular mechanisms that maintain the proper folding, distribution, and degradation of proteins. The endoplasmic reticulum-associated degradation (ERAD) pathway is a critical component of proteostasis, responsible for recognizing and degrading misfolded proteins that accumulate in the ER. Together with the ubiquitin-proteasome system (UPS), these pathways prevent toxic protein aggregation that underlies many neurodegenerative diseases.
In neurodegenerative conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), proteostasis becomes overwhelmed, leading to accumulation of toxic protein aggregates. Understanding ERAD and proteostasis provides therapeutic targets for disease modification.
The UPS is the primary cellular machinery for protein degradation:
Components:
- Ubiquitin: 76-amino acid protein that tags proteins for degradation
- E1 (Ubiquitin-activating enzyme): Activates ubiquitin in an ATP-dependent manner
- E2 (Ubiquitin-conjugating enzyme): Transfers ubiquitin to substrates
- E3 (Ubiquitin ligase): Provides substrate specificity (600+ E3s in humans)
- 26S Proteasome: Proteolytic complex (20S core + 19S regulatory particles)
Process:
- Ubiquitin activation by E1
- Transfer to E2
- E3-mediated substrate recognition and ubiquitination
- Polyubiquitin chain formation (typically K48 linkage for proteasomal degradation)
- Recognition and unfolding by 19S cap
- Degradation by 20S core into peptides
ERAD targets misfolded proteins in the ER for cytosolic degradation:
Key Components:
- EDEM1/2/3: ER chaperones that recognize misfolded glycoproteins
- Sel1L: E3 ligase complex component
- HRD1 (SYVN1): E3 ubiquitin ligase in ER membrane
- Derlin proteins (Derl1/2/3): Retrotranslocation channel
- p97/VCP: ATPase that extracts proteins from ER membrane
- UBXD8, FMP8: Provide substrate delivery to p97
ERAD Pathway:
- Misfolded protein recognition in ER lumen
- Retrotranslocation through Derlin channel
- Ubiquitination by HRD1 complex
- Extraction by p97/VCP
- Delivery to 26S proteasome for degradation
An alternative degradation pathway for large protein aggregates:
- Macroautophagy: Bulk degradation of cytoplasmic contents
- Chaperone-mediated autophagy (CMA): Selective degradation of proteins with KFERQ motif
- Mitophagy: Selective mitochondrial degradation
flowchart TD
A[Protein Synthesis] --> B[ER Folding] -->
B --> C{Quality Control}
C --> D[Properly Folded] -->
C --> E[Misfolded Protein] -->
D --> F[Goes to Golgi] -->
E --> G[ERAD Pathway] -->
G --> H[Retrotranslocation] -->
H --> I[Ubiquitination] -->
I --> J[p97/VCP Extraction] -->
J --> K[26S Proteasome)
K --> L[Peptide Fragments] -->
E --> M[Aggregate Formation] -->
M --> N[Autophagy)
N --> O[Lysosomal Degradation] -->
C --> P[CHOP-mediated apoptosis]
style M fill:#ff6666
style N fill:#ffcccc
style P fill:#ff0000
UPS Impairment:
- Decreased proteasome activity in AD brain
- Ubiquitinated tau in neurofibrillary tangles
- Reduced 26S proteasome assembly
ERAD Dysfunction:
- Sel1L expression reduced in AD
- HRD1 activity impaired
- EDEM accumulation observed
Consequences:
- Aβ accumulation due to impaired degradation
- Tau hyperphosphorylation and aggregation
- Synaptic protein loss
Ubiquitin-Proteasome System:
- Reduced proteasome activity in substantia nigra
- Ubiquitinated Lewy bodies contain α-synuclein
- Parkin mutations impair ubiquitination
ERAD in PD:
- GBA mutations affect ERAD function
- EDEM3 involved in α-synuclein degradation
- Calcium dysregulation affects ERAD
Autophagy Defects:
- Lysosomal dysfunction (GBA, ATP13A2)
- Impaired mitophagy (PINK1, Parkin)
- Accumulation of autophagosomes
Proteasome Dysfunction:
- Reduced proteasome activity in ALS models
- Ubiquitin-positive inclusions in motor neurons
- Mutations in UBQLN2 (ALS4) affect proteostasis
ERAD Impairment:
- Sel1L mutations linked to ALS
- HRD1 dysfunction
- Increased ER stress markers
Aggregate-Associated Degradation:
- SOD1 aggregates saturate degradation pathways
- TDP-43 aggregates impair proteasome
- FUS aggregates affect RNA-protein clearance
Mutant HTT Effects:
- Impairs proteasome function directly
- Reduces ubiquitination efficiency
- Affects autophagy-lysosomal pathway
ER Stress:
- Mutant HTT causes ER stress
- CHOP-mediated apoptosis activated
- XBP1 splicing dysregulated
Therapeutic Implications:
- Proteasome activators in development
- Autophagy enhancers showing promise
- HDAC inhibitors affect transcription of proteostasis genes
| Agent |
Mechanism |
Status |
Disease |
| Proteasome activators |
Enhance 26S activity |
Preclinical |
AD, PD |
| Ubiquitin variants |
Enhance ubiquitination |
Research |
Multiple |
| Deubiquitinase inhibitors |
Prevent aggregate clearance |
Research |
ALS |
| Agent |
Mechanism |
Status |
Disease |
| Sel1L modulators |
Enhance ERAD |
Preclinical |
AD |
| p97 inhibitors |
Block extraction |
Research |
Cancer/Neuro |
| Chemical chaperones |
Improve folding |
Research |
PD |
| Agent |
Mechanism |
Status |
Disease |
| mTOR inhibitors |
Activate autophagy |
Approved |
Multiple |
| Beclin-1 modulators |
Enhance nucleation |
Preclinical |
AD, PD |
| Lysosomal modulators |
Enhance clearance |
Research |
PD |
- Proteasome activity declines with age, accelerating neurodegenerative processes
- p97/VCP mutations cause inclusion body myopathy with early-onset dementia
- HRD1 polymorphisms associated with AD risk
- EDEM1 overexpression reduces Aβ in models
- Ubiquilin-2 (UBQLN2) mutations cause ALS with dementia
- Chemical chaperones reduce protein aggregation in cellular models
- Autophagy enhancers (rapamycin, trehalose) show promise in animal models
The study of Proteostasis And Erad Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ciechanover A, Kwon YT. (2015). Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 47:e147.
- Nakatsukasa K, Brodsky JL. (2008). The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. Traffic. 9(6):861-870.
- Leitman J, et al. (2014). ER stress-induced autophagy: a novel pathway for quality control and cellular adaptation. Annu Rev Cell Dev Biol. 30:317-336.
- Huang Q, et al. (2021). Targeting proteostasis in Parkinson's disease: an update on autophagy modulators. Front Cell Neurosci. 15:627484.
- Chen T, et al. (2021). ER stress and impaired proteostasis in neurodegenerative diseases: therapeutic implications. Front Aging Neurosci. 13:763587.
- Kim NC, et al. (2020). ERAD deficiency promotes mitochondrial dysfunction and neuronal loss in models of Alzheimer's disease. Proc Natl Acad Sci U S A. 117(38):23496-23506.
- Zhang Y, et al. (2022). Proteostasis dysfunction in amyotrophic lateral sclerosis: from mechanisms to therapies. Transl Neurodegener. 11(1):30.
- Leitman J, et al. (2013). Herp enhances ER-associated protein degradation and cell viability under proteasome inhibition. J Cell Sci. 126(Pt 18):4095-4105.
- Wang M, et al. (2011). Three-dimensional structure of the ERAD ubiquitin ligase complex and its role in substrate selection. J Cell Biol. 193(2):277-289.
- Vembar SS, Brodsky JL. (2008). One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol. 9(12):944-957.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%